Nipah virus does not just infect the body, it disrupts immune defences at multiple levels, suppressing early antiviral responses and triggering harmful inflammation.

Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting ...

How does the body react after contracting the deadly NiV? Expert explains how the Nipah virus attacks the brain, leading to ...

India, Jan. 29 -- As Nipah virus cases re-emerge in parts of India, including Kerala and West Bengal, health authorities ...

The discovery could serve as a starting point for antiviral strategies. A research team at Ruhr University Bochum, Germany, has identified a previously unknown cellular mechanism crucial to the ...

The virus has a fatality rate ranging from 40 per cent to 75 per cent, according to health experts. There is currently no ...

Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with ...

Using hypertonic saline nasal drops can reduce the length of the common cold in children by two days, according to a study that will be presented at the European Respiratory Society (ERS) Congress in ...

Recently, researchers in Dr. Chao Liu and Dr. Ping Zhang's team of Sun Yat-sen University identified a novel target of flavivirus protease NS2B3—diacylglycerol O-acyltransferase 2 (DGAT2), a key ...